Javier Sastre

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Jaafar Bennouna, Javier Sastre, Dirk Arnold et al. · The Lancet Oncology · 2012 · 1.2K citations · Full text

Gastrointestinal Oncology, Medicine, Randomised Phase 3 +7

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo et al. · The Lancet Oncology · 2015 · 829 citations · Full text

Oncology, Hepatology, Clinical Trials +10

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

David Goldstein, Robert H. El-Maraghi, Pascal Hammel et al. · JNCI Journal of the National Cancer Institute · 2015 · 656 citations · Full text

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

D. Machover, Eduardo Díaz‐Rubio, Aimery de Gramont et al. · Annals of Oncology · 1996 · 433 citations · Full text

Oncology, Medicine, Colorectal Cancer +5

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer

Ricardo Hitt, Juan J. Grau, Antonio López–Pousa et al. · Annals of Oncology · 2013 · 345 citations

Neck Cancer, Neoadjuvant Therapy, Radiation Therapy +11